Plunkett Research Online: Avexa Limited

AVEXA LIMITED (AVXAF:GREY) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Avexa Limited is an Australian biotechnology company with a focus on development and commercialization of small molecules for the treatment of infectious diseases. Its key anti-infective pharmaceutical programs and projects include apricitabine, an HIV integrase program and an antibiotic program for.....



Avexa Limited
Ticker: AVXAF
Exchange: GREY
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 61 392084300
Fax: 61 392084004
Address: 19 William Street
Level 5
Cremone
Sydney, VIC 3121 Australia

Types Of Business
Industry Ranks

Industry NAICS code:

Research and Development in Biotechnology
Pharmaceutical Preparation Manufacturing
ContactsDescription

Avexa Limited is an Australian biotechnology company with a focus on development and commercialization of small molecules for the treatment of infectious diseases. Its key anti-infective pharmaceutical programs and projects include apricitabine, an HIV integrase program and an antibiotic program for.....See More See More

Auditor: RSM AUSTRALIA PARTNERS
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201920182017201620152014
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: